kras mutation and glutathion JCI Uncovering new therapeutic targets for
Uncovering new therapeutic targets for a common KRAS mutation behind cancer Targeting KRAS Mutant Cancers with a Covalent G12C Specific Inhibitor: Cell kras mutation and glutathion glynac Interplays of glucose metabolism in pancreatic ductal adenocarcinoma GlyNAC Supplementation Improves Glutathione Deficiency, Targeting mutated GTPase KRAS in tumor therapies ScienceDirect Kinetic and Redox Characterization of KRAS G12C Inhibition bioRxiv Metabolic networks in mutant KRAS driven tumours: tissue specificities and the microenvironment Nature Reviews Cancer
Pay in 4 interest-free payments of $7.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10





